Advertisement

Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis

Published:November 25, 2008DOI:https://doi.org/10.1016/j.jaad.2008.09.046

      Background

      The association between psoriasis and cardiovascular diseases is well documented yet the underlying mechanisms remain elusive.

      Objectives

      We sought to study the role of circulating osteopontin (OPN) in the pathogenesis of cardiovascular diseases in patients with psoriasis.

      Methods

      Plasma samples from 40 patients with psoriasis and 37 control subjects were collected for enzyme-linked immunosorbent assays. The clinical significance of OPN levels in patients with psoriasis versus control subjects was analyzed using the Mann-Whitney U test and logistic regression. DNA samples from 268 patients with psoriasis and 146 control subjects were collected for genotyping of the OPN gene.

      Results

      Higher body mass index values (P = .047) and hypertension (odds ratio [OR] 2.68, P = .05) were observed in patients with psoriasis. Increased plasma OPN levels (≥62.95 ng/mL) were significantly associated with psoriasis (OR 6.24, P = .001), hypertension (OR 3.05, P = .03), and diabetes mellitus (OR 3.13, P = .05). Occurrence of psoriasis (OR 5.12, P = .003) appeared to be the single independent risk factor for high plasma OPN values after multivariate logistic regression. Among patients with psoriasis, increased plasma OPN values were associated with the presence of hypertension (OR 4.69, P = .05). However, no significantly different allelic distributions of single nucleotide polymorphisms of the OPN gene were found between psoriasis and control groups.

      Limitations

      The number of patients evaluated was relatively small.

      Conclusions

      High plasma OPN levels are an unfavorable factor for development of cardiovascular disease in patients with psoriasis.

      Abbreviations used:

      BMI (body mass index), CI (confidence interval), DM (diabetes mellitus), MetS (metabolic syndrome), OPN (osteopontin), OR (odds ratio), SNPs (single nucleotide polymorphisms)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McDonald C.J.
        Cardiovascular disease in psoriasis.
        J Invest Dermatol. 1989; 92: 646-647
        • Poikolainen K.
        • Karvonen J.
        • Pukkala E.
        Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis.
        Arch Dermatol. 1999; 135: 1490-1493
        • Gelfand J.M.
        • Neimann A.L.
        • Shin D.B.
        • Wang X.
        • Margolis D.J.
        • Troxel A.B.
        Risk of myocardial infarction in patients with psoriasis.
        JAMA. 2006; 296: 1735-1741
        • Neimann A.L.
        • Shin D.B.
        • Wang X.
        • Margolis D.J.
        • Troxel A.B.
        • Gelfand J.M.
        Prevalence of cardiovascular risk factors in patients with psoriasis.
        J Am Acad Dermatol. 2006; 55: 829-835
        • Herron M.D.
        • Hinckley M.
        • Hoffman M.S.
        • Paperfuss J.
        • Hansen C.B.
        • Callis K.P.
        • et al.
        Impact of obesity and smoking on psoriasis presentation and management.
        Arch Dermatol. 2005; 141: 1527-1534
        • Sommer D.M.
        • Jenisch S.
        • Suchan M.
        • Christophers E.
        • Weichenthal M.
        Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis.
        Arch Dermatol Res. 2006; 298: 321-328
        • Cohen A.D.
        • Gilutz H.
        • Henkin Y.
        • Zahger D.
        • Shapiro J.
        • Bonneh D.Y.
        • et al.
        Psoriasis and the metabolic syndrome.
        Acta Derm Venereol. 2007; 87: 506-509
        • Brown L.F.
        • Berse B.
        • Van de W.L.
        • Papadopoulos-Sergiou A.
        • Perruzzi C.A.
        • Manseau E.J.
        • et al.
        Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces.
        Mol Biol Cell. 1992; 3: 1169-1180
        • Butler W.T.
        The nature and significance of osteopontin.
        Connect Tissue Res. 1989; 23: 123-136
        • Miyazaki Y.
        • Setoguchi M.
        • Yoshida S.
        • Higuchi Y.
        • Akizuki S.
        • Yamamoto S.
        The mouse osteopontin gene: expression in monocytic lineages and complete nucleotide sequence.
        J Biol Chem. 1990; 265: 14432-14438
        • Giachelli C.M.
        • Bae N.
        • Almeida M.
        • Denhardt D.T.
        • Alpers C.E.
        • Schwartz S.M.
        Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques.
        J Clin Invest. 1993; 92: 1686-1696
        • Denhardt D.T.
        • Noda M.
        • O'Regan A.W.
        • Pavlin D.
        • Berman J.S.
        Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.
        J Clin Invest. 2001; 107: 1055-1061
        • Renkl A.C.
        • Wussler J.
        • Ahrens T.
        • Thoma K.
        • Kon S.
        • Uede T.
        • et al.
        Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype.
        Blood. 2005; 106: 946-955
        • Liaw L.
        • Almeida M.
        • Hart C.E.
        • Schwartz S.M.
        • Giachelli C.M.
        Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro.
        Circ Res. 1994; 74: 214-224
        • Giachelli C.M.
        • Liaw L.
        • Murry C.E.
        • Schwartz S.M.
        • Almeida M.
        Osteopontin expression in cardiovascular diseases.
        Ann N Y Acad Sci. 1995; 760: 109-126
        • Ikeda T.
        • Shirasawa T.
        • Esaki Y.
        • Yoshiki S.
        • Hirokawa K.
        Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta.
        J Clin Invest. 1993; 92: 2814-2820
        • Shanahan C.M.
        • Cary N.R.
        • Metcalfe J.C.
        • Weissberg P.L.
        High expression of genes for calcification-regulating proteins in human atherosclerotic plaques.
        J Clin Invest. 1994; 93: 2393-2402
        • Ohmori R.
        • Momiyama Y.
        • Taniguchi H.
        • Takahashi R.
        • Kusuhara M.
        • Nakamura H.
        • et al.
        Plasma osteopontin levels are associated with the presence and extent of coronary artery disease.
        Atherosclerosis. 2003; 170: 333-337
        • Minoretti P.
        • Falcone C.
        • Calcagnino M.
        • Emanuele E.
        • Buzzi M.P.
        • Coen E.
        • et al.
        Prognostic significance of plasma osteopontin levels in patients with chronic stable angina.
        Eur Heart J. 2006; 27: 802-807
        • Kurata M.
        • Okura T.
        • Watanabe S.
        • Fukuoka T.
        • Higaki J.
        Osteopontin and carotid atherosclerosis in patients with essential hypertension.
        Clin Sci (Colch). 2006; 111: 319-324
        • D'Alfonso S.
        • Barizzone N.
        • Giordano M.
        • Chiocchetti A.
        • Magnani C.
        • Castelli L.
        • et al.
        Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus.
        Arthritis Rheum. 2005; 52: 539-547
        • Caillier S.
        • Barcellos L.F.
        • Baranzini S.E.
        • Swerdlin A.
        • Lincoln R.R.
        • Steinman L.
        • Chu S.Y.
        • Chen C.K.
        • Chen C.M.
        • et al.
        Osteopontin polymorphisms and disease course in multiple sclerosis.
        Genes Immun. 2003; 4: 312-315
        • Xu A.P.
        • Bai J.
        • Lü J.
        • Liang Y.Y.
        • Li J.G.
        • Lai D.Y.
        • et al.
        Osteopontin gene polymorphism in association with systemic lupus erythematosus in Chinese patients.
        Chin Med J (Engl). 2007; 120: 2124-2128
        • Xu G.
        • Sun W.
        • He D.
        • Wang L.
        • Zheng W.
        • Nie H.
        • et al.
        Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism.
        J Rheumatol. 2005; 32: 410-416
        • Urcelay E.
        • Martinez A.
        • Mas-Fontao A.
        • Peris-Pertusa A.
        • Pascual-Salcedo D.
        • Balsa A.
        • et al.
        Osteopontin gene polymorphisms in Spanish patients with rheumatoid arthritis.
        J Rheumatol. 2005; 32: 405-409
        • Clark R.A.
        • Kupper T.S.
        Misbehaving macrophages in the pathogenesis of psoriasis.
        J Clin Invest. 2006; 116: 2084-2087
        • Stratis A.
        • Pasparakis M.
        • Rupec R.A.
        • Markur D.
        • Hartman K.
        • Scharffetter-Kochanek K.
        • et al.
        Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation.
        J Clin Invest. 2006; 116: 2094-2104
        • Wang H.
        • Peters T.
        • Kess D.
        • Sindrilaru A.
        • Oreshkova T.
        • Van Rooijen N.
        • et al.
        Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation.
        J Clin Invest. 2006; 116: 2105-2114
      1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).
        JAMA. 2001; 285: 2486-2497
        • Einhorn D.
        • Reaven G.M.
        • Cobin R.H.
        • Ford E.
        • Ganda O.P.
        • Handelsman Y.
        • et al.
        American College of Endocrinology position statement on the insulin resistance syndrome.
        Endocr Pract. 2003; 9: 237-252
        • Schottelius A.J.
        • Moldawer L.L.
        • Dinarello C.A.
        • Asadullah K.
        • Sterry W.
        • Edwards III, C.K.
        Biology of tumor necrosis factor-alpha implications for psoriasis.
        Exp Dermatol. 2004; 13: 193-222
        • Torre-Amione G.
        • Kapadia S.
        • Lee J.
        • Durand J.B.
        • Bies R.D.
        • Young J.B.
        • et al.
        Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart.
        Circulation. 1996; 93: 704-711
        • Kubota T.
        • McTiernan C.F.
        • Frye C.S.
        • Slawson S.E.
        • Lemster B.H.
        • Koretsky A.P.
        • et al.
        Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha.
        Circ Res. 1997; 81: 627-635
        • Wakkee M.
        • Thio H.B.
        • Prens E.P.
        • Sijbrands E.J.
        • Neumann H.A.
        Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients.
        Atherosclerosis. 2007; 190: 1-9
        • Malerba M.
        • Gisondi P.
        • Radaeli A.
        • Sala R.
        • Calzavara Pinton P.G.
        • Girolomoni G.
        Plasma homocysteine and folate levels in patients with chronic plaque psoriasis.
        Br J Dermatol. 2006; 155: 1165-1169
        • Vanizor Kural B.
        • Orem A.
        • Cimşit G.
        • Uydu H.A.
        • Yandi Y.E.
        • Alver A.
        Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients.
        Clin Chim Acta. 2003; 332: 23-30
        • Johnston A.
        • Arnadottir S.
        • Gudjonsson J.E.
        • Aphale A.
        • Sigmarsdottir A.A.
        • Gunnarsson S.I.
        • et al.
        Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation.
        Br J Dermatol. 2008; 159: 342-350
        • Wang Y.
        • Chen J.
        • Zhao Y.
        • Geng L.
        • Song F.
        • Chen H.D.
        Psoriasis is associated with increased levels of serum leptin.
        Br J Dermatol. 2008; 158: 1134-1135
        • Chen Y.J.
        • Wu C.Y.
        • Shen J.L.
        • Chu S.Y.
        • Chen C.K.
        • Chen C.M.
        • et al.
        Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome.
        Arch Dermatol. 2008; 144: 12
        • Unni E.
        • Kittrell F.S.
        • Singh U.
        • Sinha R.
        Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine.
        Breast Cancer Res. 2004; 6: R586-R592
        • Mason C.K.
        • McFarlane S.
        • Johnston P.G.
        • Crowe P.
        • Erwin P.J.
        • Domostoj M.M.
        Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation.
        Mol Cancer Ther. 2008; 7: 548-558
        • Kapoor S.
        Inhibition of osteopontin dependent carcinogenesis.
        J Cancer Res Clin Oncol. 2008; 134: 927-928
        • de Las Fuentes L.
        • Gu C.C.
        • Mathews S.J.
        • Reagan J.L.
        • Ruthmann N.P.
        • Waggoner A.D.
        • et al.
        Osteopontin promoter polymorphism is associated with increased carotid intima-media thickness.
        J Am Soc Echocardiogr. 2008; 21: 954-960
        • Brenner D.
        • Labreuche J.
        • Touboul P.J.
        • Schmidt-Petersen K.
        • Poirier O.
        • Perret C.
        • et al.
        Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients.
        Stroke. 2006; 37: 1691-1696